The Optimal Radioimmunotherapy Combinations for Advanced TNBC

This study aims to explore the best combination patterns of radiotherapy and immunotherapy for advanced triple-negative breast cancer (TNBC).

Trial Details

NCT ID
NCT06735131
Phase
PHASE2
Sponsor
Sun Yat-sen University
Status
RECRUITING
Cancer Type
Triple Negative (TNBC) Breast Cancer
Interventions
  • radiotherapy 5 Gy × 5 fractions, once a day
  • radiotherapy 8 Gy × 5 fractions, once a day
  • radiotherapy 8 Gy × 3 fractions, once every other day
  • radiotherapy 10 Gy× 3 fractions, once every other day
  • radiotehrapy 0.5Gy twice-a-day × 2 days, repeat for 4 cycles (total 8Gy)
  • Toripalimab
Locations (sample)
  • Guangzhou, Guangdong, China|23.11667,113.25

Key Eligibility Criteria

  • Inoperable locally advanced/metastatic triple-negative breast cancer (defined as ER and PR \<1%; and HER2 negative as IHC 0 or IHC 1+, or IHC 2+ bu…
  • No prior chemotherapy for advanced/metastatic disease.
  • ECOG PS score of 0 or 1.
  • Presence of 1 to 5 tumor lesions suitable for radiotherapy (individual lesion size between 0.5 and 5 cm, not limited to 1 to 2 organs).

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.

Find Triple Negative (TNBC) Breast Cancer Trials on Trialify →